SynOV1.1, a lysogenic adenovirus with a synthetic genetic circuit consisting of an α-fetoprotein promoter and miRNA responsive target elements that control specific replication in alpha-fetoprotein (AFP)-positive tumor cells, has been approved by the FDA [90]. Here, AFP is linked to neoplasm.